Exploring new ways to uncover factors that keep HIV hidden in the body
HIV-CRISPR: A novel approach to the comprehensive discovery of HIV latency factors
This study is looking at how HIV can stay hidden in the body, making it tough to get rid of completely, and it's for people living with HIV who want to know more about new ways to treat the virus beyond just taking medication every day.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10812476 on NIH RePORTER |
What this research studies
This research focuses on understanding how HIV can remain dormant in the body, making it difficult to completely eliminate the virus. By using advanced genetic screening techniques, the study aims to identify the factors that contribute to HIV latency, which is when the virus hides in cells and evades the immune system. The approach involves activating these hidden viruses and then using immunological methods to target and destroy the infected cells. This could lead to more effective treatments that go beyond current lifelong antiretroviral therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who are currently on antiretroviral therapy and are interested in potential new treatment options.
Not a fit: Patients who are not living with HIV or those who are not on antiretroviral therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to breakthroughs in curing HIV by effectively targeting and eliminating latent virus reservoirs.
How similar studies have performed: While there have been various approaches to understanding HIV latency, this innovative genetic screening method represents a novel strategy that has not been extensively tested before.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Emerman, Michael — Fred Hutchinson Cancer Center
- Study coordinator: Emerman, Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.